What the changes say
- Lite Strategy added risks regarding its new Litecoin holding strategy and crypto asset market regulations.
What changed since the prior 10-K
New
- NewRisks Related to Investing in Litecoin
The price of Litecoin has been and will likely continue to be, highly volatile
Litecoin price volatility could result in converting holdings to cash below purchase cost, and Litecoin holdings are less liquid than cash.
- NewRisks Related to Investing in Litecoin
The launch of central bank digital currencies (CBDCs) may adversely impact our business
Government-issued central bank digital currencies could reduce demand for private cryptocurrencies like Litecoin.
- NewRisks Related to Investing in Litecoin
We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition and results of operations
New or unclear regulations and securities laws applied to digital assets could negatively impact Litecoin prices and our stock.
- NewRisks Related to Investing in Litecoin
Regulatory change reclassifying Litecoin as a security could lead to our falling within the definition of “investment company” under the Investment Company Act of 1940, as amended, or the 1940 Act and could adversely affect the market price of Litecoin and the market price of our common stock
Reclassifying Litecoin as a security could trigger investment company status under the Investment Company Act of 1940.
- NewRisks Related to Investing in Litecoin
We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers
We do not comply with Investment Company Act regulations, leaving our Board with broad discretion over leverage, custody, and Litecoin strategy.
- NewRisks Related to Investing in Litecoin
significant regulatory scrutiny, investigations, fines, penalties and other legal, regulatory, contractual and financial exposure
Cybersecurity attacks or data breaches on digital asset networks could cause a loss of confidence in the Litecoin ecosystem.
- NewRisks Related to Our Financial Condition and Capital Requirements
Whenever we resume development of our drug candidates or any future drug candidate, we may need to raise additional capital to continue such development
Resuming development of drug candidates voruciclib and zandelisib will increase R&D expenses and require raising additional capital.
Dropped
- DroppedRisks Related to Our Review of Strategic Alternatives
We may not be successful in identifying and implementing any potential strategic alternatives in a timely manner, or at all, and any strategic transactions that we may consummate in the future could have negative consequences
Exploration of strategic alternatives to maximize stockholder value announced in July 2024.
- DroppedRisks Related to Our Review of Strategic Alternatives
identify, negotiate and consummate such transaction. If we are unable to successfully retain certain of our key remaining personnel, we are at risk of a disruption to our exploration and consummation of one or more strategic transactions
Retention of key personnel during strategic transactions and counterparties valuing assets.
- DroppedRisks Related to Our Review of Strategic Alternatives
about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up
Stockholder risk of losing investment in a liquidation or winding up.
- DroppedRisks Related to Our Review of Strategic Alternatives
We may become involved in litigation, including securities class action litigation, that could divert our management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages
Litigation and SEC investigations following strategic transactions or negative events.
- DroppedRisks Related to Our Review of Strategic Alternatives
Our workforce reduction may not achieve our intended outcome and may result in significant adverse consequences
Workforce reduction consequences including loss of institutional knowledge and decreased morale.
- DroppedRisks Related to Our Financial Condition and Capital Requirements
enter into, and our expenditures on other research and development (R&D) activities as well as any payments owed under the License Agreement with Presage and any future similar agreements
- DroppedRisks Related to Our Financial Condition and Capital Requirements
If we decide to resume development of our drug candidate or any future drug candidate, we will need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our drug development programs
- DroppedRisks Related to Our Financial Condition and Capital Requirements
In July 2024, we discontinued the clinical program in our pipeline in connection with our undertaking a comprehensive exploration of strategic alternatives focused on maximizing stockholder value. In connection with our streamlined operating plan, we commenced a reduction-in-force
Future R&D expenditures and payments under the Presage License Agreement.
- DroppedRisks Related to Our Intellectual Property
respect to the use of their isoflavone compounds, including ME-344. Finally, in September 2013, we acquired patents and patent applications related to zandelisib from Pathway Therapeutics, Inc
- DroppedGeneral Business Risks
prospective European clinical trial sites and CROs to use our products, and we may find it necessary or desirable to make further changes to our processing of personal data of EEA or U.K. data subjects
Funding needs if drug development resumes.
- DroppedRisks Related to Securities Markets and Investment in our Stock
Anson Advisors Inc. holds approximately 16.4% of our outstanding common stock and Cable Car Capital LLC holds approximately 9.2% of our outstanding common stock, and each have sought to exert influence on our business operations and Board, and we expect that each will or may continue to do so
Discontinuation of clinical programs and reduction-in-force announced in July 2024.
Reworded
- 74% rewrittenRisks Related to Our Financial Condition and Capital Requirements
Should we resume development activities in the future, we expect that R&D costs would increase and we would continue to incur expenses and operating and net losses, as we develop and seek development and/or commercial relationships with other partners for such drug candidates
Updated to reflect potential R&D resumption expenses, net losses, and the Presage License Agreement.
Was: Should we resume development activities in the future, we expect that research and development costs would increase significantly and we would continue to incur significant expenses and operating and net losses, as we develop and seek regulatory approval for such drug candidates
- 72% rewrittenRisks Related to Our Intellectual Property
The value of our intellectual property is dependent, in part, on obtaining and maintaining patent protection and preserving trade secrets, which cannot be guaranteed
Added specific patent acquisitions for voruciclib from Presage in 2017 and zandelisib from Pathway Therapeutics in 2013.
- 57% rewrittenRisks Related to Our Financial Condition and Capital Requirements
We have incurred significant losses from our inception and we anticipate that we may incur losses in the foreseeable future
Updated financial figures for fiscal 2025 net loss of $15.9 million and noted the October 2024 sale of ME-344.
- 39% rewrittenRisks Related to Securities Markets and Investment in our Stock
Future sales of our common stock, including common stock issued upon exercise of outstanding warrants or options, may depress the market price of our common stock and cause stockholders to experience dilution
Updated warrant and option counts as of June 30, 2025, including post-year-end issuance of warrants for 3,070,177 shares.
- 36% rewrittenRisks Related to Our Financial Condition and Capital Requirements
add operational, financial and management information systems and personnel, including personnel to support our drug development efforts
Added risk that deciding to resume drug candidate development may require unfunded capital raising.
Was: add operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts
- 35% rewrittenRisks Related to Securities Markets and Investment in our Stock
Other than as described below or in connection with a strategic transaction we do not intend to pay and we have not paid, any cash dividends on our shares of common stock. Our stockholders will not be able to receive a return on their shares unless the value of our common stock appreciates and they sell their shares
Removed mention of the Capital Return dividend from historical cash dividend disclosures.
- 33% rewrittenRisks Related to Securities Markets and Investment in our Stock
If we fail to comply with the continued listing standards of the Nasdaq Capital Market, we may be delisted and the price of our common stock, our ability to access the capital markets and our financial condition could be negatively impacted
Updated Nasdaq ticker symbol from MEIP to LITS.
- 32% rewrittenGeneral Business Risks
Our efforts will be seriously jeopardized if we are unable to retain and attract key employees
Added availability of consultants or third-party scientific personnel alongside key employee retention risks.
- 29% rewrittenGeneral Business Risks
Security breaches and privacy issues could compromise our information and expose us to liability, which would cause our business and reputation to suffer
- 22% rewrittenRisks Related to Securities Markets and Investment in our Stock
The trading price of the shares of our common stock has been and may continue to be highly volatile and could decline in value and we may incur significant costs from class action litigation
All 33 risk factors
Headings as the filing states them, in filing order.
Risks Related to Investing in Litecoin
- 01The price of Litecoin has been and will likely continue to be, highly volatileNew
- 02The launch of central bank digital currencies (CBDCs) may adversely impact our businessNew
- 03We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition and results of operationsNew
- 04Regulatory change reclassifying Litecoin as a security could lead to our falling within the definition of “investment company” under the Investment Company Act of 1940, as amended, or the 1940 Act and could adversely affect the market price of Litecoin and the market price of our common stockNew
- 05We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisersNew
- 06significant regulatory scrutiny, investigations, fines, penalties and other legal, regulatory, contractual and financial exposureNew
Risks Related to Our Financial Condition and Capital Requirements
- 07We have incurred significant losses from our inception and we anticipate that we may incur losses in the foreseeable future57% rewritten
- 08Should we resume development activities in the future, we expect that R&D costs would increase and we would continue to incur expenses and operating and net losses, as we develop and seek development and/or commercial relationships with other partners for such drug candidates74% rewritten
- 09add operational, financial and management information systems and personnel, including personnel to support our drug development efforts36% rewritten
- 10Whenever we resume development of our drug candidates or any future drug candidate, we may need to raise additional capital to continue such developmentNew
- 11the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish
Risks Related to Any Future Development and Commercialization of Our Drug and Potential Drug Candidates
- 12Should we resume development of our drug candidate or future drug candidates, if we are unable to successfully complete clinical development, obtain regulatory approvals and commercialize our drug candidate or future drug candidates, or experience significant delays in doing so, our business will be materially harmed
Risks Related to Our Intellectual Property
- 13The value of our intellectual property is dependent, in part, on obtaining and maintaining patent protection and preserving trade secrets, which cannot be guaranteed72% rewritten
General Business Risks
- 14Our employees, independent contractors, consultants or commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business
- 15Our business and operations would suffer in the event of system failures
- 16Our efforts will be seriously jeopardized if we are unable to retain and attract key employees32% rewritten
- 17Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial markets or collaborators
- 18Laws, rules and regulations relating to public companies may be costly and impact our ability to attract and retain directors and executive officers
- 19Security breaches and privacy issues could compromise our information and expose us to liability, which would cause our business and reputation to suffer29% rewritten
- 20If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business
- 21We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
- 22Limitations on the deductibility of net operating losses could adversely affect our business and financial condition
Risks Related to Securities Markets and Investment in our Stock
- 23We are currently operating in a period of capital markets disruption and economic uncertainty
- 24If we fail to comply with the continued listing standards of the Nasdaq Capital Market, we may be delisted and the price of our common stock, our ability to access the capital markets and our financial condition could be negatively impacted33% rewritten
- 25The trading price of the shares of our common stock has been and may continue to be highly volatile and could decline in value and we may incur significant costs from class action litigation22% rewritten
- 26threatened or actual delisting of our common stock from a national stock exchange
- 27Future sales of our common stock, including common stock issued upon exercise of outstanding warrants or options, may depress the market price of our common stock and cause stockholders to experience dilution39% rewritten
- 28Other than as described below or in connection with a strategic transaction we do not intend to pay and we have not paid, any cash dividends on our shares of common stock. Our stockholders will not be able to receive a return on their shares unless the value of our common stock appreciates and they sell their shares35% rewritten
- 29We will have broad discretion over the use of the net proceeds from any exercise of outstanding warrants and options
- 30We are authorized to issue blank check preferred stock, which could adversely affect the holders of our common stock
- 31Anti-takeover provisions contained in our amended and restated certificate of incorporation and sixth amended and restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt
- 32Any person or entity purchasing or otherwise acquiring or holding any interest in our shares of capital stock shall be deemed to have notice of and consented to such provisions
- 33Our executive officer and directors may sell shares of their stock and these sales could adversely affect our stock price
Other Lite Strategy 10-Ks
- FY2026 10-K risk factors27 risks1 new3 dropped6 reworded
Lite Strategy now emphasizes its Litecoin Treasury Strategy and exposure to LTC price volatility alongside potential pre-clinical drug programs.
Filed Sep 28, 2026 - FY2024 10-K risk factors37 risks
Lite Strategy is actively exploring strategic alternatives and has discontinued clinical programs like voruciclib and ME-344, implementing a workforce reduction. Significant risks include potential delisting from Nasdaq, activist pressure from major shareholders Anson Advisors and Cable Car Capital, and the need to secure additional capital if development resumes.
Filed Sep 19, 2024
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.